IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Jan-2024
Active ingredients
durvalumab
Proposed indication
For use in neodjuvant/adjuvant resectable non-small cell lung cancer.
Application type
C (new indication)
Publication date
Jan-2024